UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Asthma prevalence in 1973, 1988 and 2003

Thorax, 2006-04, Vol.61 (4), p.296-299

2006

Volltextzugriff (PDF)

P229 Should home oxygen assessment be part of the respiratory virtual ward?

Thorax, 2023-11, Vol.78 (Suppl 4), p.A250-A251

2023

Volltextzugriff (PDF)

P209 Adherence and quality of life in COPD is improved by a fixed triple therapy: the TriOptimize study

Thorax, 2023-11, Vol.78 (Suppl 4), p.A237-A238

2023

Volltextzugriff (PDF)

P4 Nebulised medications in secondary care: rising to the challenge

Thorax, 2022-11, Vol.77 (Suppl 1), p.A82-A82

2022

Volltextzugriff (PDF)

848 Dynamic chest X-ray and associated spirometry in people with cystic fibrosis

Journal of cystic fibrosis, 2024-09, Vol.23, p.S492-S492

2024

Volltextzugriff (PDF)

159 Inter-relatedness of changes in clinical trial endpoints in cystic fibrosis

Journal of cystic fibrosis, 2024-09, Vol.23, p.S89-S90

2024

Volltextzugriff (PDF)

EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?

Journal of cystic fibrosis, 2024-06, Vol.23, p.S64-S64

2024

Volltextzugriff (PDF)

P429 The role of Cystic Fibrosis Nurse Specialist in the Annual Reviewprocess for adults living with CF in the post-modulator era: A single centre experience

Journal of cystic fibrosis, 2024-06, Vol.23, p.S199-S199

2024

Volltextzugriff (PDF)

P48 Have we taken any steps to reduce the environmental impacts of inhalers? A perspective from a specialist respiratory team in a deprived area of the UK

Thorax, 2023-11, Vol.78 (Suppl 4), p.A134-A134

2023

Volltextzugriff (PDF)

354 Defining cardiac risk, events, and outcomes in people living with cystic fibrosis: a multisource, multinational approach

Journal of cystic fibrosis, 2023-10, Vol.22, p.S179-S179

2023

Volltextzugriff (PDF)

Risk of major cardiovascular events and bleeding in atrial fibrillation patients with chronic obstructive pulmonary disease treated with low dose azithromycin prophylaxis

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

P167 ‘Stay alert, control the virus, save lives’. Do neutralising monoclonal antibodies really live up to the hype?

Thorax, 2022-11, Vol.77 (Suppl 1), p.A171-A172

2022

Volltextzugriff (PDF)

P225 Pulmonary Rehabilitation in Long COVID – The impact of social deprivation and treatment delay on outcomes

Thorax, 2022-11, Vol.77 (Suppl 1), p.A204-A204

2022

Volltextzugriff (PDF)

P227 Community acquired pneumonia and readmissions from the virtual ward

Thorax, 2023-11, Vol.78 (Suppl 4), p.A249-A250

2023

Volltextzugriff (PDF)

P230 Predicators of COPD exacerbation readmissions from the virtual ward

Thorax, 2023-11, Vol.78 (Suppl 4), p.A251-A251

2023

Volltextzugriff (PDF)

WS01.06 Evaluating trends in cardiovascular events in people with cystic fibrosis before and after elexacaftor/tezacaftor/ivacaftor initiation – a retrospective review in federated electronic healthcare record

Journal of cystic fibrosis, 2024-06, Vol.23, p.S2-S3

2024

Volltextzugriff (PDF)

The viral aetiology of croup and recurrent croup

Archives of disease in childhood, 2009-05, Vol.94 (5), p.359-360

2009

Volltextzugriff (PDF)

P257 Development and validation of a machine learning model to predict antimicrobial resistance in people living with cystic fibrosis using routinely collected electronic healthcare record data

Journal of cystic fibrosis, 2024-06, Vol.23, p.S147-S147

2024

Volltextzugriff (PDF)

S31 Home oxygen therapy and smoking: playing with fire?

Thorax, 2021-11, Vol.76 (Suppl 2), p.A23-A23

2021

Volltextzugriff (PDF)

P80 Ambivalence or blind faith? Attitudes and experiences in a community CURE respiratory smoking cessation services

Thorax, 2021-11, Vol.76 (Suppl 2), p.A110-A111

2021

Volltextzugriff (PDF)

WS10.03 Increasing cardiovascular risk in adults with cystic fibrosis related diabetes receiving CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor)

Journal of cystic fibrosis, 2023-06, Vol.22, p.S20-S21

2023

Volltextzugriff (PDF)

P216 The impact of the COVID-19 pandemic and elexacaftor/tezacaftor/ivacaftor initiation on high-cost medication utilisation in adults living with cystic fibrosis

Journal of cystic fibrosis, 2023-06, Vol.22, p.S131-S131

2023

Volltextzugriff (PDF)

EPS1.10 Prevalence, risk factors and outcomes of cardiovascular disease in cystic fibrosis: retrospective cohort study in two large patient data registries

Journal of cystic fibrosis, 2023-06, Vol.22, p.S39-S40

2023

Volltextzugriff (PDF)

156 Influenza and Swine Flu vaccination coverage in adult cystic fibrosis

Journal of cystic fibrosis, 2012-06, Vol.11, p.S96-S96

2012

Volltextzugriff (PDF)

P134 Outcomes from pulmonary rehabilitation in patients with interstitial lung disease

Thorax, 2021-02, Vol.76 (Suppl 1), p.A161-A161

2021

Volltextzugriff (PDF)

1 – 25 von 281

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(218)
Mit Volltextzugriff
(192)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(111)
Life Sciences & Biomedicine
(82)
Humans
(78)
Female
(66)
Male
(60)
Biological And Medical Sciences
(55)
Adult
(50)
Medical Sciences
(50)
Middle Aged
(40)
Risk Factors
(29)
Aged
(25)
Fundamental And Applied Biological Sciences. Psychology
(21)
Prospective Studies
(20)
Endocrinopathies
(19)
Endocrinology & Metabolism
(18)
Technology
(18)
Materials Science
(16)
Animals
(15)
Prevalence
(14)
Adolescent
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Asthma prevalence in 1973, 1988 and 2003

P229 Should home oxygen assessment be part of the respiratory virtual ward?

P209 Adherence and quality of life in COPD is improved by a fixed triple therapy: the TriOptimize study

P4 Nebulised medications in secondary care: rising to the challenge

848 Dynamic chest X-ray and associated spirometry in people with cystic fibrosis

159 Inter-relatedness of changes in clinical trial endpoints in cystic fibrosis

EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?

P429 The role of Cystic Fibrosis Nurse Specialist in the Annual Reviewprocess for adults living with CF in the post-modulator era: A single centre experience

P48 Have we taken any steps to reduce the environmental impacts of inhalers? A perspective from a specialist respiratory team in a deprived area of the UK

354 Defining cardiac risk, events, and outcomes in people living with cystic fibrosis: a multisource, multinational approach

Risk of major cardiovascular events and bleeding in atrial fibrillation patients with chronic obstructive pulmonary disease treated with low dose azithromycin prophylaxis

P167 ‘Stay alert, control the virus, save lives’. Do neutralising monoclonal antibodies really live up to the hype?

P225 Pulmonary Rehabilitation in Long COVID – The impact of social deprivation and treatment delay on outcomes

P227 Community acquired pneumonia and readmissions from the virtual ward

P230 Predicators of COPD exacerbation readmissions from the virtual ward

WS01.06 Evaluating trends in cardiovascular events in people with cystic fibrosis before and after elexacaftor/tezacaftor/ivacaftor initiation – a retrospective review in federated electronic healthcare record

The viral aetiology of croup and recurrent croup

P257 Development and validation of a machine learning model to predict antimicrobial resistance in people living with cystic fibrosis using routinely collected electronic healthcare record data

S31 Home oxygen therapy and smoking: playing with fire?

P80 Ambivalence or blind faith? Attitudes and experiences in a community CURE respiratory smoking cessation services

WS10.03 Increasing cardiovascular risk in adults with cystic fibrosis related diabetes receiving CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor)

P216 The impact of the COVID-19 pandemic and elexacaftor/tezacaftor/ivacaftor initiation on high-cost medication utilisation in adults living with cystic fibrosis

EPS1.10 Prevalence, risk factors and outcomes of cardiovascular disease in cystic fibrosis: retrospective cohort study in two large patient data registries

156 Influenza and Swine Flu vaccination coverage in adult cystic fibrosis

P134 Outcomes from pulmonary rehabilitation in patients with interstitial lung disease

Suchergebnisse filtern